Treatments & Services

Available Trials

A randomized, multicenter, double blind Phase 3 study of PD-0332991 (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

 

Bladder

Breast

Hematology

Leukemia

Lung

  • Trilaciclib/Placebo with Atezolizumab in Small Cell Lung Cancer

    Phase 2 Study of Carbplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28) in Patients with Untreated Extensive Stage Small Cell Lung Cancer


  • Nivolumab in Advanced NSCLC

    A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies


Lymphoma

  • Brentuximab Vedotin in combination with Nivolumab for Hodgkins Lymphoma

    A phase 2 open-label study of Brentuximab Vedotin in combination with Nivolumab in front-line therapy of Hodgkin Lymphoma (HL) in adults age 60 and above


  • Rituximab +/- Ibrutinib for Follicular Lymphoma

    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma


  • TGR-1202 in patients with DLBCL, FL, SLL, or MZL

    A phase 2b randomized study to assess the efficacy and safety of the combination of Ublituximab + TGR-1202 and TGR-1202 alone in patients with previously treated Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma


  • ACP-196 and Pembrolizumab in B-cell Malignancies

    ACP-196 and Pembrolizumab in B-cell Malignancies


  • Lenalidomide/Rituxan for FL, MZ, ML

    A phase 3b randomized study of Lenalidomide (CC-5013) plus Rituximab maintenance therapy followed by Lenalidomide single-agent maintenance versus Rituximab maintenance in subjects with relapsed/refractory Follicular, Marginal Zone or Mantle Cell Lymphoma


Prostate

Renal

Solid Tumors